1. Home
  2. NXL

as of 09-01-2026 9:36am EST

$6.73
$0.50
-6.92%
Stocks Health Care Medical Specialities Nasdaq

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Founded: 2010 Country:
United States
United States
Employees: N/A City: HOUSTON
Market Cap: 7.5M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 139.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.21 EPS Growth: 39.76
52 Week Low/High: $0.22 - $7.69 Next Earning Date: 05-11-2026
Revenue: $301,647 Revenue Growth: 78.78%
Revenue Growth (this year): 15.52% Revenue Growth (next year): 100.00%
P/E Ratio: -32.38 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: